Drugs / BCMA-TGFβ CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05976555 | Jul 2026 → May 2028 expected | plasma cell myeloma | Medical College of Wisconsin | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA-TGFβ CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05976555 ↗ |
| Known as | BCMA-Transforming growth factor-beta (TGFβ) CAR-T cells | “BCMA-Transforming growth factor-beta (TGFβ) CAR-T cells will be administered either fresh or thawed after cryopreservation by IV injection.” NCT05976555 ↗ |
| Modality | Cell therapy | “manufactured CAR T cells” NCT05976555 ↗ |
| Route | Intravenous | “by IV injection” NCT05976555 ↗ |